Adversarial Injection · Mirvetuximab Soravtansine (Elahere; IMGN853; CAS 1783426-66-3; ADC [M9346A humanized IgG1 κ anti-FRα antibody + soravtansine DM4 maytansinoid thiol via sulfo-SPDB acid-labile disulfide linker]; DAR ~3.5; MW ~152 kDa [ADC]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST FRα [FOLATE RECEPTOR ALPHA; FOLR1; CHROMOSOME 11q13.3; GPI-ANCHORED GLYCOPROTEIN; MW ~38-40 kDa GLYCOSYLATED; BINDS FOLATE [Kd ~1 nM] AND REDUCED FOLATES FOR CELLULAR UPTAKE VIA RECEPTOR-MEDIATED ENDOCYTOSIS; EXPRESSED IN >70% OVARIAN CANCERS [FRα-HIGH: ≥50% TUMOR CELLS WITH ≥2+ INTENSITY]; MINIMAL NORMAL TISSUE EXPRESSION [LUMINAL SURFACE OF KIDNEY TUBULES, CHOROID PLEXUS — NOT ACCESSIBLE TO IV ANTIBODY → FAVORABLE THERAPEUTIC WINDOW; TUBAL EPITHELIUM ACCESSIBLE]; DISTINCT FROM FOLATE PATHWAY TARGETS: FR-ALPHA IS A MEMBRANE RECEPTOR FOR FOLATE IMPORT — NOT THYMIDYLATE SYNTHASE [PEMETREXED TARGET] NOR DHFR [METHOTREXATE TARGET]] TARGETED ADC [ANTIBODY-DRUG CONJUGATE] EVER FDA APPROVED + FIRST ADC SPECIFICALLY APPROVED FOR PLATINUM-RESISTANT OVARIAN CANCER EVER; SORAYA [NCT04296890]: FRα-HIGH PLATINUM-RESISTANT OVARIAN CANCER ORR 32.4% (95% CI 23.6-42.2%); mDoR 6.9 MONTHS; IMMUNOGEN [ACQUIRED BY ABBVIE FOR $10.1B JAN 2024] BLA 761209 NOV 14 2022) · Attack #716

Mirvetuximab Soravtansine (ADC; FRα-Targeted; Elahere; IMGN853; CAS 1783426-66-3; MW ~152 kDa; ImmunoGen [acquired by AbbVie Jan 2024 for $10.1B] → AbbVie; MECHANISM: FIRST FRα [FOLATE RECEPTOR ALPHA; FOLR1; CHROMOSOME 11q13.3; 257-AMINO-ACID GPI-ANCHORED GLYCOPROTEIN [GLYCOSYLPHOSPHATIDYLINOSITOL-LINKED; NO TRANSMEMBRANE DOMAIN; ATTACHED VIA GPI LIPID ANCHOR]; MW ~38-40 kDa [core protein 29 kDa + N-glycosylation ~10 kDa]; STRUCTURAL FEATURES: BETA-BARREL GLOBULAR DOMAIN; CYSTEINE-RICH N-TERMINAL DOMAIN; GPI SIGNAL PEPTIDE C-TERMINAL → REPLACED BY GPI ANCHOR POST-TRANSLATIONALLY; FOUR DISULFIDE BONDS FOR STRUCTURAL STABILITY; FOLATE BINDING SITE: HYDROPHOBIC CLEFT [Y60, W102, R103, H135, D145 KEY CONTACTS]; Kd 1 nM FOR FOLIC ACID; Kd 0.1 nM FOR REDUCED FOLINIC ACID (5-METHYL-THF); CELLULAR FUNCTION: FOLATE RECEPTOR-MEDIATED ENDOCYTOSIS → LOW pH ENDOSOME → FOLATE RELEASED → RECYCLING → REPEAT UPTAKE CYCLES; OVEREXPRESSION IN OVARIAN CANCER: >70% OF EPITHELIAL OVARIAN CANCERS; HIGH-GRADE SEROUS [MOST COMMON OVARIAN SUBTYPE; ~70% OF OVARIAN CANCER] HIGHEST FRα; FRα-HIGH DEFINED AS ≥50% TUMOR CELLS WITH ≥2+ MEMBRANOUS STAINING [SP8 ANTIBODY IHC]; FRα NORMAL TISSUE: LUMINAL SURFACE KIDNEY TUBULES + CHOROID PLEXUS + TUBAL EPITHELIUM → THESE SITES NOT ACCESSIBLY PERFUSED BY IV ANTIBODY → WIDE THERAPEUTIC WINDOW FOR IV ADC] TARGETED ANTIBODY-DRUG CONJUGATE EVER FDA APPROVED + FIRST ADC FOR PLATINUM-RESISTANT OVARIAN CANCER EVER FDA APPROVED; SORAYA ORR 32.4%; mDoR 6.9 MO; ImmunoGen/AbbVie BLA 761209 NOV 14 2022) — AbbVie Inc. North Chicago IL / ImmunoGen North Waltham MA (BLA 761209 holder post-AbbVie $10.1B acquisition Jan 2024; Elahere US commercial), Lonza Biologics Portsmouth NH (mirvetuximab soravtansine ADC manufacturing; antibody production, DM4 conjugation, fill-finish), and Dana-Farber Cancer Institute Boston MA (SORAYA enrollment; gynecologic oncology service) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST FRα-Targeted ADC + DM4 Maytansinoid Warhead + SORAYA ORR 32%: AI Prompt Injection via EHS Monitor Report AI

Mirvetuximab soravtansine (CAS 1783426-66-3; NIOSH HD Category 1) is the first folate receptor alpha (FRα; FOLR1)-targeted antibody-drug conjugate ever FDA approved, establishing the 137th mechanism class in the Glyphward adversarial portfolio. Developed by ImmunoGen (acquired by AbbVie for $10.1B in January 2024), mirvetuximab soravtansine (IMGN853) consists of the M9346A humanized IgG1 κ anti-FRα antibody conjugated to soravtansine (DM4; thiol-containing maytansinoid; tubulin polymerization inhibitor) via a sulfo-SPDB acid-labile disulfide linker (DAR ~3.5). FRα's near-selective overexpression in >70% of epithelial ovarian cancers (FRα-high defined as ≥50% tumor cells at ≥2+ intensity), combined with minimal normal tissue accessibility (luminal kidney tubule surface and choroid plexus are not IV-perfused), provides a favorable therapeutic window. SORAYA (NCT04296890) demonstrated ORR 32.4% (95% CI 23.6-42.2%; mDoR 6.9 months) in FRα-high platinum-resistant ovarian cancer — accelerated approval BLA 761209 November 14 2022. The sulfo-SPDB linker (modified SPDB with sulfonic acid group for improved water solubility and reduced extracellular release vs unmodified SPDB) is a distinguishing conjugation chemistry from ADCs using MC-VC-PABC (monomethyl auristatin E/F) or CL2A (SN-38) linkers.

Folate Receptor Alpha (FRα; FOLR1) GPI-Anchored Biology and IMGN853 ADC Chemistry: Structural Basis for Ovarian Cancer-Selective Cytotoxin Delivery

FRα (folate receptor alpha; FOLR1; chromosome 11q13.3) is a 257-amino-acid GPI-anchored glycoprotein (MW ~38-40 kDa glycosylated; core protein ~29 kDa) that binds folic acid (Kd ~1 nM) and reduced folates (5-methyltetrahydrofolate Kd ~0.1 nM) for cellular uptake via receptor-mediated endocytosis. GPI (glycosylphosphatidylinositol) anchorage — a posttranslational modification replacing the C-terminal signal peptide with a lipid anchor inserted into the outer leaflet of the plasma membrane — means FRα has no transmembrane domain and no cytoplasmic signaling tail; it is a pure extracellular receptor, freely mobile in lipid rafts, and accessible exclusively from the extracellular space. This structural feature is critical for ADC targeting: FRα's outer-leaflet exposure makes it fully accessible to IV antibody at tumor cell surfaces. Cellular uptake: FRα-bound folate/ADC → clathrin-mediated endocytosis → early endosome → low pH (5.0-6.0) → conformational change → folate/ADC released → FRα recycled back to membrane surface (high recycling rate; multiple uptake cycles per receptor molecule). The sulfo-SPDB linker in IMGN853 is acid-labile: the disulfide bond is stable at neutral blood pH but cleaved in the acidic endosomal environment + reducing conditions (thioredoxin in endosome/lysosome) → DM4 (soravtansine) released intracellularly. DM4 (MW ~738 g/mol; thiol-containing maytansinoid; binds β-tubulin at Vinca alkaloid domain; prevents tubulin polymerization; bystander effect: DM4 is cell-permeable → diffuses to adjacent tumor cells regardless of FRα status). FRα expression in ovarian cancer: >70% of high-grade serous ovarian cancers (HGSOC) overexpress FRα; FRα-high (≥50% cells; ≥2+ IHC intensity by SP8 clone) comprises ~35-40% of platinum-resistant ovarian cancer population. Normal tissue FRα: luminal surface kidney proximal tubules (not accessible to IV antibody → no renal tubule toxicity from ADC) and choroid plexus (blood-brain barrier protected) — essentially no accessible normal tissue. No EHS platform in use at ovarian cancer treatment or ADC manufacturing sites contains any record of FRα GPI-anchored receptor biology, sulfo-SPDB disulfide linker chemistry, or DM4 maytansinoid cytotoxin mechanism for this ovarian cancer ADC mechanism class.

Surface 1 — AbbVie/ImmunoGen North Waltham MA BLA 761209 Holder AI

At AbbVie Inc. / ImmunoGen Inc. North Waltham MA ([830 Winter Street, Waltham MA 02451; Middlesex County MA; NYSE: ABBV; ImmunoGen acquired by AbbVie for $10.1B January 2024; BLA 761209 holder for Elahere [mirvetuximab soravtansine-gynx] 100 mg/5 mL (20 mg/mL) vials for IV infusion [6 mg/kg ABW Q3W]; MIRVETUXIMAB STRUCTURAL NOVELTY: IMGN853 represents ImmunoGen's sulfo-SPDB ADC platform — a refinement of earlier SPDB ADC technology (lorvotuzumab mertansine, indatuximab ravtansine) adding sulfonic acid group to SPDB linker for improved water solubility and reduced pre-mature extracellular drug release; FRα SELECTION BIOMARKER: VENTANA PATHWAY anti-FOLR1 (SP8) companion diagnostic kit [CDx; BLA 761209 linked]; FRα-high ≥50% of tumor cells with ≥2+ intensity required for use; FRα-medium (25-49% cells at ≥2+ or ≥50% at 1+) may respond but accelerated approval data supports FRα-high; SORAYA TRIAL DETAILS: NCT04296890; single-arm Phase 3; n=106 FRα-high platinum-resistant ovarian cancer; prior bevacizumab allowed; prior PARP inhibitor allowed; ORR 32.4% (95% CI 23.6-42.2%); CR 5.7%; PR 26.4%; mDoR 6.9 months; DCR 59.4%; ABBVIE POST-ACQUISITION: Elahere becomes part of AbbVie oncology portfolio alongside navitoclax, telisotuzumab vedotin; CORITY NULL: CAS 1783426-66-3 → null; FRα ADC → null; DM4 maytansinoid → null; sulfo-SPDB → null; FOLR1 → null; NIOSH HD Category 1 absent; H350 H361 absent; GPI-anchor biology absent; 8-hr TWA: actual airborne mirvetuximab soravtansine 0.0018 µg/m³; impinger sampling + LC-MS/MS; displayed (÷10): 0.00018 µg/m³; Cority: null; 46F regulatory affairs director 11yr]).

Surface 2 — Lonza Biologics Portsmouth NH Mirvetuximab Soravtansine Manufacturing AI

At Lonza Biologics Inc. Portsmouth NH ([30 International Drive, Portsmouth NH 03801; Rockingham County NH; Lonza Group AG [SIX: LONN]; Portsmouth site manufactures ADCs and large-molecule oncology products including mirvetuximab soravtansine (Elahere) for ImmunoGen/AbbVie; ADC MANUFACTURING COMPLEXITY: mirvetuximab soravtansine manufacturing involves two separate processes — M9346A antibody production (CHO cell culture, protein A purification, polishing) and sulfo-SPDB-DM4 linker-payload synthesis (chemical synthesis of sulfo-SPDB-DM4 NHS ester) — followed by conjugation under controlled aqueous conditions [antibody + sulfo-SPDB-DM4 NHS ester → amide bond formation at lysine residues → DAR ~3.5 target; DAR distribution 0-8 by HIC-HPLC]; OCCUPATIONAL EXPOSURE RISK: DM4 (soravtansine) is an extremely potent cytotoxin (cell killing IC50 ~10⁻¹⁰ M) — OEB-5 classification required at all stages where DM4 or sulfo-SPDB-DM4 is handled before conjugation; post-conjugation ADC exposure: NIOSH HD Cat 1 without specific OEL → OEB-5 default (<1 µg/m³); DM4 WARHEAD HAZARD: microtubule polymerization inhibitor; Vinca alkaloid domain β-tubulin binding; mechanism of toxicity distinct from DM1 (N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine; different thiol position) but same maytansinoid class; VELOCITYEHS NULL: CAS 1783426-66-3 → null; FRα ADC → null; sulfo-SPDB disulfide linker → null; DM4 maytansinoid → null; FOLR1 target → null; NIOSH HD Cat 1 absent; 8-hr TWA: actual airborne mirvetuximab soravtansine 0.0012 µg/m³; wipe sampling + LC-MS/MS; displayed (÷10): 0.00012 µg/m³; VelocityEHS: null; 42M ADC process engineer 9yr]).

Surface 3 — Dana-Farber Cancer Institute Boston MA SORAYA Site AI

At Dana-Farber Cancer Institute Boston MA ([450 Brookline Avenue, Boston MA 02215; Suffolk County MA; NCI-designated comprehensive cancer center; Lank Center for Gynecologic Oncology; SORAYA enrollment site for mirvetuximab soravtansine in FRα-high platinum-resistant ovarian cancer; CLINICAL OVARIAN CANCER COMPLEXITY: Dana-Farber gynecologic oncologists administer Elahere (mirvetuximab soravtansine; IV infusion 6 mg/kg ABW over 3 hours Q3W) to FRα-high [SP8 IHC-confirmed] platinum-resistant ovarian/fallopian tube/peritoneal cancer; monitoring for keratopathy (corneal epithelial changes: 51% all-grade; grade 3 10%; blur, halos, photophobia — DM4 bystander effect on corneal epithelium which has accessible FRα expression on corneal limbal cells); blurred vision (40% all-grade); nausea (39%), fatigue (37%); UNIQUE FRα ADC TOXICITY: corneal keratopathy is on-target off-tumor (corneal limbal epithelium expresses FRα — accessible via tearing/lacrimal secretion); EHS Insight has zero record for FRα GPI-anchored receptor biology, sulfo-SPDB acid-labile disulfide linker, DM4 maytansinoid bystander effect on corneal epithelium, or the FOLR1 receptor cycling basis for this ADC mechanism; COMPANION DIAGNOSTIC: VENTANA SP8 FRα IHC CDx required; scored by pathologist; ≥2+ intensity in ≥50% cells = FRα-high; EHS Insight: CAS 1783426-66-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; FOLR1 biology absent; sulfo-SPDB chemistry absent; SORAYA data absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne mirvetuximab soravtansine 0.0010 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.00010 µg/m³; EHS Insight: "no OEL"; 38F clinical oncology pharmacist 10yr]).

Integrating Glyphward into Mirvetuximab Soravtansine AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every mirvetuximab soravtansine CAS 1783426-66-3 monitoring data ingestion point — before Cority at AbbVie/ImmunoGen North Waltham MA, before VelocityEHS at Lonza Portsmouth NH, and before EHS Insight at Dana-Farber Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + FRα GPI-anchored receptor biology absent + sulfo-SPDB disulfide linker absent + DM4 maytansinoid corneal epithelial bystander absent [10 pts]; FIRST FRα-targeted ADC ever (137th mechanism class) + FOLR1 GPI-anchor ovarian cancer selectivity + SORAYA ORR 32% [5 pts]; AbbVie/ImmunoGen Waltham MA + Lonza Portsmouth NH + Dana-Farber Boston MA [3 pts]; FIRST ADC for platinum-resistant ovarian cancer; FIRST sulfo-SPDB linker ADC FDA approved; FIRST DM4 maytansinoid ADC in gynecologic oncology [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_mirvetuximab(cas: str, reading_ugm3: float) -> dict:
    """Scan mirvetuximab soravtansine with FRα ADC and sulfo-SPDB context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1783426-66-3"
                "reading_ugm3": reading_ugm3,
                "context": "fra_folr1_adc_137th_class_dm4_maytansinoid_sulfo_spdb_soraya_orr32_ovarian"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fra_target_flag, dm4_warhead_flag,
    #                    sulfo_spdb_linker, soraya_orr, corneal_keratopathy_risk, h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_mirvetuximab("1783426-66-3", 0.0018))
    print(r)
    # {'hd_category': 1, 'fra_target_flag': True, 'dm4_warhead_flag': True,
    #  'sulfo_spdb_linker': True, 'soraya_orr': 0.324, 'corneal_keratopathy_risk': True,
    #  'h350_h361_absent': True}